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Abstract
Background: There are limited data available on macrolide-lincosamide-streptogramin (MLS) resistance of
Staphylococcus aureus (S. aureus) and coagulase-negative staphylococci (CoNS) from bovine milk in China. To
address this knowledge gap, MLS resistance was determined in 121 S. aureus and 97 CoNS isolates. Minimum
inhibitory concentrations (MICs) of MLS antibiotics were determined by an agar dilution method, while
differentiation of MLS phenotypes was performed by a double-disc diffusion test. MLS resistance genotypes were
determined by PCR for corresponding resistance genes.
Results: Forty (33.1 %) S. aureus and 65 (67.0 %) CoNS were resistant to erythromycin, whereas all 218 isolates were
susceptible to quinupristin/dalfopristin. Among 40 erythromycin-resistant (ER-R) S. aureus and 65 ER-R CoNS isolates,
38 S. aureus and 40 CoNS isolates exhibited the inducible MLS (iMLS) resistance phenotype and 2 S. aureus and 20
CoNS isolates expressed the constitutive MLS resistance (cMLS) phenotype. At the same time, 5 CoNS isolates
exhibited resistance to erythromycin but susceptibility to clindamycin (the MS phenotype). An inactivating enzyme
gene lnu(A), methylase genes erm(C) and erm(B), efflux genes msr(A)/msr(B), a phosphotransferase gene mph(C), an
esterase gene ere(A) and the streptogramin resistance determinant vga(A) were detected individually or in
combinations. Among them, genes lnu(A), erm(C) and mph(C) predominated. The ereA gene was detected for the
first time in staphylococci of bovine milk origin. Resistance genes also existed in erythromycin-susceptible isolates.
Conclusions: Our study demonstrated a high level of resistance to MLS antibiotics in staphylococci from bovine
mastitic milk, especially with a high rate of the iMLS phenotype in S. aureus isolates. These data suggest that MLS
antibiotics should be used judiciously to treat or prevent bovine mastitis caused by staphylococci.
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Background
Bovine mastitis is the most costly disease for the dairy in-
dustry worldwide. Although a wide variety of pathogens
have been isolated as causative agents of this disease,
Staphylococcus aureus (S. aureus) is considered as one of
the most important pathogens due to its resistance to cer-
tain antibiotics and its propensity to recur chronically. Re-
cently, coagulase-negative staphylococci (CoNS) have been
considered as opportunistic pathogens that cause bovine
mastitis in many countries and could be therefore described
as emerging mastitis pathogens [1, 2]. Increasing attention
has been paid to CoNS in both subclinical and clinical
mastitis cases throughout the world [3, 4]. Macrolide-
lincosamide-streptogramin (MLS) antibiotics, including
erythromycin, clindamycin and spiramycin, are frequently
used for treatment of bovine mastitis [5, 6]. Thus, results
from an in vitro susceptibility testing are an important
tool to guide a veterinarian in selecting the most effica-
cious antimicrobial agent(s) for therapeutic and prophy-
lactic intervention.
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Three mechanisms are mainly responsible for acquiring
resistance to MLS antibiotics in staphylococci: (1) target
site modifications by methylation or mutation; (2) active ef-
flux of antibiotics; or (3) inactivation of antibiotics. The first
mechanism includes target site modifications by a methyl-
ase encoded by one or more of the erm genes, methylating
23S rRNA and thereby altering binding sites for MLS anti-
biotics [7]. Phenotypically, this resistance appears either in-
ducible (resistant to 14- and 15-membered macrolides and
susceptible to 16-membered macrolides, lincosamides and
streptogramin B) or constitutive (resistant to all forms of
these antibiotics) [8]. The second mechanism involves a
macrolide efflux pump encoded by msr(A) and/or msr(B)
genes. This pump protein belongs to the ABC transporter
family and exports 14-membered macrolides and strepto-
gramin B antibiotics from bacterial cells, while lincosamide
and streptogramin A antibiotics remain unaffected (the MS
phenotype) [9]. The third mechanism encompasses several
enzymes. A lincosamide nucleotidyltransferase encoded by
the lnu(A) gene confers resistance only to lincosamides and
has been detected in CoNS isolates from bovine mastitis
[10]. Esterases encoded by ere(A)/(B) genes hydrolyze the
lactone ring of the macrocyclic nucleus [11]. Furthermore,
vga(A)/(B) genes have been characterized as a determinant
of streptogramin A resistance [11]. Finally, the macrolide
phosphotransferase C encoded by the mph(C) gene inacti-
vates some macrolide antibiotics and has been detected in
CoNS isolated from bovine subclinical mastitis [12].
The reported resistance of S. aureus and CoNS isolated
from bovine mastitis to MLS antibiotics in different coun-
tries was generally low [12, 13]. Meanwhile, there was a
paucity of data regarding MLS-resistance phenotypes and
genotypes of S. aureus and CoNS isolated from bovine
mastitis in China, except one study [5]. The objective of
this study was to determine the MLS resistance pheno-
types and genotypes of 121 S. aureus and 97 CoNS isolates
from mastitic milk from dairy farms of the Shaanxi prov-
ince in Northwestern China.
Methods
Bacterial isolates
Milk samples were obtained from dairy cows with clinical
mastitis under the ethical approval granted by the College
of Animal Science and Technology, the Northwest
Agriculture and Forestry (A&F) University (Permit
Number: NWAFU1008), as described previously [14]. A
total of 121 coagulase-positive S. aureus (CoPSA) and 97
coagulase-negative staphylococci (CoNS) were used in this
study. CoNS species were identified by sequencing analyses
based on sodA and/or gap genes [14]. Ninety-seven CoNS
isolates encompassed 9 CoNS species: Staphylococcus hae-
molyticus (S. haemolyticus, n = 31), Staphylococcus aureus
(S. aureus, n = 28), Staphylococcus chromogenes (S. chromo-
genes, n = 11), Staphylococcus sciuri (S. sciuri, n = 9),
Staphylococcus epidermidis (S. epidermidis, n = 7),
Staphylococcus simulans (S. simulans, n = 5), Staphylo-
coccus hyicus (S. hyicus, n = 3), Staphylococcus warneri
(S. warneri, n = 2) and Staphylococcus saprophyticus
(S. saprophyticus, n = 1).
Antibiotic susceptibility testing
Minimum inhibitory concentrations (MICs) of antimicro-
bial agents, including 14-membered (erythromycin), 15-
membered (azithromycin), 13- and 15-membered mixture
(tulathromycin) and 16-membered (tylosin and spiramycin)
macrolides, lincosamides (clindamycin) and streptogramins
(quinupristin/dalfopristin) were determined using an agar
dilution method. Clindamycin, azithromycin, tulathromycin
and spiramycin were purchased from Dalian Meilun
Biology Technology Co., Ltd. (Dalian, China). Tylosin was
purchased from Shanghai Kai Yang Biotechnology Co., Ltd.
(Shanghai, China). Erythromycin was bought from Sigma-
Aldrich (Beijing, China) and quinupristin/dalfopristin was
obtained from Santa Cruz biotechnology, Inc. (Shanghai,
China). The approved veterinary specific CLSI MIC break-
points of erythromycin and clindamycin are ≥ 8 μg/mL and
4 μg/mL, respectively [15]. MIC breakpoint for spira-
mycin (≥32 μg/mL) was adopted from the Swedish
Antibiotic Utilisation and Resistance in Human Medicine
(SWEDRES) and Swedish Veterinary Antimicrobial
Resistance Monitoring (SVARM) system (SWEDRES-
SVARM) [16]. The MIC breakpoint for tylosin (≥20 μg/mL)
was based on the Veterinary Antimicrobial Decision
Support (VADS) according to a previous study [5]. There
were no veterinary specific CLSI, VADS or SWEDRES-
SVARM-approved breakpoints for azithromycin and
quinupristin-dalfopristin. Therefore, we used a human spe-
cific CLSI document M100-S21 [17] as a reference to de-
termine breakpoints for azithromycin (≥8 μg/mL) and
quinupristin-dalfopristin (≥4 μg/mL). In addition, there
was no CLSI, VADS or SVARM-approved breakpoint for
tulathromycin. The standard reference strain S. aureus
ATCC 29213 served as a quality control in every test run.
Detection of MLS resistance phenotypes
In order to differentiate different types of resistance pheno-
type for erythromycin-resistant (ER-R) isolates, a double-
disk diffusion test (D test) was performed with erythro-
mycin (15 μg/disc) and clindamycin (2 μg/disc), following
the procedure recommended by CLSI [17]. Staphylococcal
isolates showing resistance to erythromycin (zone
size ≤13 mm) but being sensitive to clindamycin (zone
size ≥21 mm) and producing a D-shaped zone of inhib-
ition around clindamycin with flattening towards
erythromycin disc was defined as having an inducible
type of MLS resistance (D+, iMLS). In addition, resistance
to erythromycin (zone size ≤13 mm) as well as to clinda-
mycin (zone size ≤14 mm) indicated a constitutive type of
Li et al. BMC Veterinary Research  (2015) 11:168 Page 2 of 8
MLS resistance (cMLS). Staphylococcal isolates showing
resistance to erythromycin (zone size ≤13 mm) while
being sensitive to clindamycin (zone size ≥21 mm) with
no blunting zone were classified as the MS phenotype.
Detection of MLS resistance genotypes
Staphylococcal isolates were incubated in the Brain Heart
Infusion broth (Oxoid) at 37 °C for 16-18 h. Then, bacteria
were harvested by centrifugation. Plasmid and chromosome
DNA of bacterial isolates were extracted using a commer-
cial DNAout kit (Tiandz Inc., Beijing, China) as described
previously [14]. The screening of MLS resistance determi-
nants including methylase genes erm(A), erm(B) and
erm(C); phosphotransferase genes mph(A) and mph(C); lin-
cosamide nucleotidyltransferase genes lnu(A) and lnu(B);
erythromycin esterase genes ere(A) and ere(B); streptogra-
min resistance genes vga(A), vga(B), vgb(A) and vgb(B), and
the macrolide efflux determinants msr(A)/msr(B) was per-
formed by PCR using the specific primers as described in
previous studies [11, 12, 18–20]. PCR products were ran-
domly selected and sequenced to ensure specificity and
accuracy. Sequence comparisons were performed using the
Basic Local Alignment Search Tool (BLAST) program
(http://www.ncbi.nlm.nih.gov/BLAST/).
Results and discussion
Characterization of MLS resistance phenotypes in
erythromycin-resistant isolates and MIC distribution
Of the 121 coagulase-positive S. aureus (CoPSA) isolates,
40 were resistant to at least one MLS antibiotic. Thirty-
eight out of 40 ER-R CoPSA (95 %) isolates exhibited iMLS
phenotypes, whereas only 2 isolates expressed cMLS phe-
notypes, with no MS phenotype. The MICs of the macro-
lides and lincosamides antibiotics for the 40 ER-R CoPSA
isolates are summarized in Table 1. Among ER-R CoPSA,
100 %, 100 %, 80 %, 17.5 % and 5 % of isolates were
resistant to erythromycin, azithromycin, spiramycin, tylosin
and clindamycin, respectively. The MIC50 and MIC90
values of 14-membered, 15-membered macrolides and
16-membered macrolide spiramycin were ≥128 μg/mL,
while the MIC50 values of 16-membered macrolides
tylosin and lincosamides were in the susceptible range.
No isolate expressed resistance to quinupristin/dalfopristin
(MICs ≤ 1 μg/mL).
Among 97 CoNS isolates, 65 isolates exhibited MLS
resistance phenotypes. Among them, 40 showed the iMLS
phenotype and 20 expressed the cMLS phenotype, while 5
exhibited the MS phenotype. The MICs of the antimicro-
bial agents tested are summarized in Table 2. Eighteen
isolates with cMLS phenotypes exhibited a high-level of
resistance to erythromycin, clindamycin, azithromycin, spir-
amycin and tylosin with MIC values of ≥256 μg/mL. Fur-
thermore, 1 S. haemolyticus with the iMLS phenotype
exhibited MICs ≥256 μg/mL for erythromycin and azithro-
mycin while MICs for spiramycin and tylosin were
64 μg/mL and 128 μg/mL, respectively. In addition, 39
CoNS isolates with the iMLS phenotype showed a
complete cross-resistance to erythromycin and azithromy-
cin with MICs of ≥256 μg/mL. However, MIC values of
16-membered macrolides tylosin (2-8 μg/mL) and spira-
mycin (2-16 μg/mL) were in the susceptible ranges.
The iMLS phenotype rate of ER-R S. aureus (38/40) and
ER-R CoNS (40/65) isolates was much higher in this study
than previous studies, underlining the importance of rou-
tine screening of bovine S. aureus and CoNS isolates for in-
ducible resistance phenotypes. Wang et al. [5] reported that
the inducible MLS resistance phenotype was detected in 38
out of 72 S. aureus isolates from cows with clinical mastitis
in Inner Mongolia of China. In another study, only 3 iso-
lates with the iMLS phenotype were found out of 22 ER-R
CoNS in Germany [12]. The reason for the higher rate of
the iMLS phenotype in our study is not clear.
Table 1 Minimum inhibitory concentrations (MICs) of 40 ER-R coagulase-positive S. aureus isolates
Antibiotic agents The number of isolates inhibited in different MICs (μg mg-1)a MIC50 MIC90
≤0.125 0.25 0.5 1 2 4 8 16 32 64 128 ≥256
Erythromycinb 0 0 0 0 0 0 0 1 3 2 6 28 >256 >256
Clindamycinb 24 7 0 1 6 0 0 0 0 0 0 2 0.125 2
Spiramycinc 0 0 0 0 0 0 3 5 0 2 30 0 >128 >128
Tylosind 0 0 3 5 25 0 0 0 2 2 2 1 2 64
Azithromycinb 0 0 0 0 0 0 0 0 0 4 0 36 >256 >256
Quinupristin-dalfopristinb 23 11 6 0 0 0 0 0 0 0 0 0 0.125 0.25
Tulathromycine 0 0 0 0 0 0 0 0 0 0 5 35 >256 >256
aSusceptibility, intermediate resistance and resistance are shown in normal, italic and boldface fonts, respectively
bMIC breakpoints for erythromycin, azithromycin, clindamycin and quinupristin-dalfopristin were based on Clinical and Laboratory Standards Institute (CLSI) documents
(CLSI, 2004, 2011)
cMIC breakpoints of spiramycin were based on the SWEDRES-SVARM (2012)
dMIC breakpoints of tylosin were based on the VADS according to a previous study [5]
eMIC breakpoints of this antibiotic were not available
MIC50, the MIC for 50 % of the organisms
MIC90, the MIC for 90 % of the organisms
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Table 2 Minimum inhibitory concentrations (MICs) of 97 CoNS isolates
Test agent Species The number of isolates inhibited in different MICs (μg mg-1)a
0.125 0.25 0.5 1 2 4 8 16 32 64 128 ≥256
Erythromycinb S. chromogenes 2 3 1 5
S. sciuri 2 5 1 1
S. warneri 1 1
S. haemolyticus 1 30
S. epidermidis 1 6
S. hyicus 3
S. saprophyticus 1
S. simulans 1 4
S. aureus 12 5 1 10
Clindamycinb S. chromogenes 6 1 3 1
S. sciuri 1 7 1
S. warneri 2
S. haemolyticus 1 8 10 12
S. epidermidis 1 1 4 1
S. hyicus 3
S. saprophyticus 1
S. simulans 3 2
S. aureus 16 6 6
Spiramycinc S. chromogenes 2 3 3 2 1
S. sciuri 1 5 2 1
S. warneri 2
S. haemolyticus 3 1 13 1 13
S. epidermidis 1 1 2 2 1
S. hyicus 3
S. saprophyticus 1
S. simulans 3 2
S. aureus 3 5 17 3
Tylosind S. chromogenes 1 7 2 1
S. sciuri 6 2 1
S. warneri 1 1
S. haemolyticus 13 4 1 1 12
S. epidermidis 1 1 4 1
S. hyicus 3
S. saprophyticus 1
S. simulans 2 1 2
S. aureus 2 20 5 1
azithromycinb S. chromogenes 1 1 3 1 5
S. sciuri 2 5 1 1
S. warneri 2
S. haemolyticus 1 30
S. epidermidis 1 6
S. hyicus 3
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Characterization of MLS resistance genotypes in
erythromycin-resistant isolates
Among 40 ER-R CoPSA isolates, the most dominant resist-
ance gene was erm(C) (38/40), followed by the mph(C)
(27/40), erm(B) (14/40), ere(A) (14/40) and vga(A) (10/40)
(Table 3). The msr(A)/msr(B) genes were found in 6 iso-
lates, which were all positive for erm(C) or erm(B) genes
and displayed iMLS phenotypes (Table 4). Considering the
65 ER-R CoNS isolates, msr(A)/msr(B) genes were present
in 51 isolates, erm(C) in 46, erm(B) in 23, mph(C) in 25,
vga(A) in 23 and ere(A) in 9 isolates. At least one of the
MLS resistance genes was detected in each ER-R isolate.
The simultaneous presence of two or more MLS antibiotic
resistance genes was also detected (Table 4). The simultan-
eous presence of two or more macrolide resistance genes
in the same S. aureus or CoNS isolate is well-known and
has been reported previously for S. aureus or CoNS isolates
from bovine mastitis [5, 12, 21].
Correlation between the MIC values of MLS resistance
phenotypes and phenotypes
The possible relationship between MLS resistance phe-
notypes and genotypes was also explored. Among the 40
ER-R CoPSA isolates, 8 isolates with iMLS phenotypes
were sensitive to 16-membered macrolides spiramycin and
32 isolates with iMLS phenotypes were sensitive to tylosin.
Those isolates were all erm(B) and/or erm(C) positive. As
for the 65 ER-R CoNS isolates, 4 erm(B) and/or erm(C)
positive isolates with the MS phenotype and 28 erm(B)
and/or erm(C) positive isolates with the iMLS phenotype
were sensitive to 16-membered macrolides spiramycin and
tylosin, respectively. Furthermore, 1 S. warneri with the
MS phenotype and 9 CoNS isolates with the iMLS pheno-
type were also sensitive to 16-membered macrolides spira-
mycin and tylosin. Those 10 isolates were negative for erm
genes but positive for other MLS resistance genes, such as
msr(A)/(B), mph(C), ere(A), lnu(A) or vga(A). In general,
erm-carrying ER-R S. aureus and CoNS isolates with iMLS
or MS phenotypes possessed a high degree of resistance to
erythromycin, azithromycin and clindamycin (inducible),
while having a low rate of resistance to 16-membered
macrolides tylosin and/or spiramycin.
It has been reported that the lactone rings of 16- and
14-membered macrolides adopt distinctly diverse confor-
mations, thereby enabling the former compounds to avoid
steric hindrance with the nucleotide A2058 mutation in
Table 2 Minimum inhibitory concentrations (MICs) of 97 CoNS isolates (Continued)
S. saprophyticus 1
S. simulans 1 4
S. aureus 6 4 2 6 10
quinupristin-dalfopristinb S. chromogenes 1 5 4 1
S. sciuri 1 8
S. warneri 1 1
S. haemolyticus 5 23 3
S. epidermidis 6 1
S. hyicus 2 1
S. saprophyticus 1
S. simulans 5
S. aureus 1 1 7 18 1
Tulathromycine S. chromogenes 3 3 1 1 3
S. sciuri 2 6 1
S. warneri 1 1
S. haemolyticus 1 8 2 20
S. epidermidis 1 1 5
S. hyicus 3
S. saprophyticus 1
S. simulans 1 2 2
S. aureus 12 5 1 3 3 4
aIntermediate resistance and resistance are shown in italic and boldface fonts, respectively
bMIC breakpoints for erythromycin, azithromycin, clindamycin and quinupristin-dalfopristin were based on Clinical and Laboratory Standards Institute (CLSI) documents
(CLSI, 2004, 2011)
cMIC breakpoints of spiramycin were based on the SWEDRES-SVARM (2012)
dMIC breakpoints of tylosin were based on the VADS according to a previous study [5]
eMIC breakpoints of this antibiotic were not available
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E. coli [22]. Such a mechanism may be also responsible for
differential sensitivity to 16- and 14-membered macrolides
in staphylococci. In addition, differential effects of 14 and
15-membered macrolides versus 16-membered macrolides
on expression of erm genes could contribute to our re-
sults. Expression of erm genes can be either inducible or
constitutive. Inducible erm genes expression is controlled
at a post-transcriptional level, which involves a structure
upstream from the erm gene composing of a leader pep-
tide and a series of inverted repeats. Formation of different
mRNA secondary structures in this regulatory region in
the presence or absence of an inducer allows or prevents
the translation of the erm gene transcripts [8]. Only 14-
and 15-membered macrolide can induce erm expression,
while 16-membered macrolides, lincosamides, or strepto-
gramins are not able to induce erm gene expression [8].
However, why 10 CoNS without the erm gene were also
sensitive to 16-membered macrolides spiramycin and
tylosin in this study is unclear and will be further studied.
In addition, previous studies have shown that erm gene
expression can quickly and irreversibly switch from indu-
cible expression to constitutive expression under selective
pressure due to the structural alterations (sequence dele-
tions of varying length, duplications and mutations),






Phenotype The number of isolates containing resistance genes
iMLS % cMLS % MS % lnuA ermB ermC msrA/B mphC ereA vgaA
S. chromogenes 11 6 5 83.3 1 16.7 0 0 6 2 3 3 1 1 2
S. sciuri 9 2 0 50 1 0 1 50 2 2 0 1 0 0 0
S. warneri 2 2 0 0 0 0 2 100 2 1 0 1 1 0 0
S. haemolyticus 31 30 18 62 12 40 0 0 30 11 22 26 14 4 12
S. epidermidis 7 6 5 83.3 1 16.7 0 0 6 2 6 7 1 1 1
S. hyicus 3 3 0 0 3 100 0 0 3 3 2 2 1 1 1
S. saprophyticus 1 1 0 0 0 0 1 100 1 0 1 1 1 0 1
S. simulans 5 4 2 50 2 50 0 0 4 0 2 2 1 0 4
CoN S. aureusa 28 11 10 91 0 0 1 9 11 3 10 8 5 2 2
Total CoNS 97 65 40 61.5 20 30.8 5 7.7 65 23 46 51 25 9 23
CoP S. aureusb 121 40 38 95 2 5 0 0 40 14 38 6 27 14 10
iMLS, inducible expression of clindamycin resistance
cMLS, constitutive expression of clindamycin resistance
MS, erythromycin-resistant, clindamycin-susceptible, no induction
CoN S. aureusa, coagulase-negative S. aureus
CoP S. aureusb, coagulase-positive S. aureus






ermB + ermC ermC +msrA/msrB ermC +mphC ermC+ msrA/msrB + mphC
n iMLS cMLS MS n iMLS cMSL MS n iMLS cMLS MS n iMLS cMLS MS
S. chromogenes 11 6 1 1 1 1 1 1
S. sciuri 9 2
S. warneri 2 2
S. haemolyticus 31 30 11 5 6 19 12 7 12 8 4 11 5 6
S. epidermidis 7 6 1 1 4 3 1 1 1 1 1
S. hyicus 3 3 2 2 2 2 1 1
S. saprophyticus 1 1 1 1 1 1 1 1
S. simulans 5 4 1 1 1 1 1 1
CoN S. aureusa 28 11 2 2 8 7 1 5 4 1 3 2 1
Total CoNS 97 65 17 8 9 0 36 23 11 2 21 14 5 2 18 9 7 2
CoP S. aureusb 121 40 18 17 1 0 6 6 0 0 27 26 1 0 6 5 1 0
iMLS, inducible expression of clindamycin resistance
cMLS, constitutive expression of clindamycin resistance
MS, erythromycin-resistant, clindamycin-susceptible, no induction
CoN S. aureusa, coagulase-negative S. aureus
CoP S. aureusb, coagulase-positive S. aureus
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which then renders the respective staphylococcal isolate
resistant to all 14-, 15-, and 16-membered macrolides, lin-
cosamides and streptogramin B antibiotics [23–25].
Therefore, different conformational rearrangements in
the mRNA structure or structural alterations (dele-
tions, duplications or mutations) in the upstream
regulatory region of erm genes could be one of the
plausible reasons of our isolates and such resistance
mechanism will be further studied.
Other resistance genes may also play a role in the
sensitivity to 16-membered macrolides. For example,
msr(A)/msr(B) genes in CoPSA isolates. These genes
encode an inducible efflux pump which is an ABC
transporter. 14- and 15-membered macrolides are in-
ducers and substrates for the pump, while clindamycin
is neither an inducer nor a substrate [8]. In our research,
all 6 msr(A)/msr(B)-carrying CoPSA isolates were also
erm(B) and/or erm(C) genes positive. These isolates had the
iMLS phenotype and exhibited MICs of ≥256 μg/mL for
erythromycin while susceptible to 16-membered macrolides
spiramycin and/or tylosin. However, the situation is much
complicated for 51 msr(A)/msr(B)-carrying CoNS isolates.
Among them, 31 (17 S. haemolyticus, 7 S. aureus, 4 S. epi-
dermidis and 3 S. chromogenes) had the iMLS phenotype,
15 (9 S. haemolyticus, 2 S. simulans, 2 S. hyicus, 1 S. epider-
midis and 1 S. chromogenes) had the cMLS phenotype and
5 (2 S. warneri, 1 S. sciuri, 1 S. aureus and 1 S. saprophyti-
cus) had the MS phenotype.
Characterization of MLS resistance genotypes in
erythromycin-susceptible isolates
Among 81 erythromycin-susceptible (ER-S) CoPSA iso-
lates, 79 isolates were positive for lnu(A), 69 for erm(C),
47 for mph(C), 66 for erm(B), 64 for msr(A)/(B), 20 for
ere(A) and 10 for vga(A) genes (Table 5), but all were
susceptible to the corresponding antibiotics (erythro-
mycin, azithromycin, spiramycin, tylosin or clindamy-
cin) in the antibiotic susceptibility testing, due to
unknown reasons. As for 32 ER-S CoNS isolates, 7, 9,
20, 11, 7 and 9 CoNS isolates harbored erm(B), erm(C),
msr(A)/(B), mph(C), ere(A), vga(A) genes, respectively
(Table 5). Furthermore, the lincosamide nucleotidyl-
transferase gene, lnu(A), was detected in all ER-R S.
aureus, ER-R CoNS isolates, ER-S CoNS and 79 ER-S
CoPSA isolates (Table 3; Table 5). The presence of
lnu(A) among staphylococcal isolates from bovine mas-
titis has been reported [5, 10, 12]. The lnu(A) gene is
mainly carried by small rolling-circle plasmids and it
mediates only a low-level of resistance to the lincosa-
mide pirlimycin [10]. The ere(A) gene was detected for
the first time in staphylococci of bovine milk origin.
Our results are in agreement with previous studies
which detected erm(C), lnu(A), mph(C) or erm(A) genes
in susceptible S. aureus or CoNS isolates [12, 26, 27].
When Martineau et al. [26] subcultured 4 erythromycin
susceptible strains harboring the erm(C) gene with in-
creasing concentration of the antibiotic, they found that
those susceptible strains all become resistant. Thus, we
need to be vigilant when we use MLS antibiotics on
dairy farms.
Conclusions
In summary, a very high rate of iMLS (95 %, 38/40)
phenotype of ER-R S. aureus and MLS resistance pheno-
type (67 %, 65/97) of CoNS isolates from milk of mastitic
cows was found in this study in comparison with previous
studies, presumably due to extensive use of MLS antibi-
otics in dairy cows in our region. Our results suggest that
MLS antibiotics should be used judiciously for therapeutic
and prophylactic intervention of staphylococci infection.






ermB ermC msrA/B mphC ereA lnuA vgaA
n % n % n % n % n % n % n %
S. chromogenes 11 5 1 20 1 20 2 40 3 60 5 100
S. sciuri 9 7 1 14.3 1 14.3 4 57.1 7 100 1 14.3 7 100
S. warneri 2 0
S. haemolyticus 31 1 1 100 1 100
S. epidermidis 7 1 1 100 1 100 1 100 1 100
S. hyicus 3 0
S. saprophyticus 1 0
S. simulans 5 1 1 100 1 100 1 100 1 100
CoN S. aureusa 28 17 4 23.5 6 35.3 15 88.2 2 11.8 1 5.9 17 100 8 47.1
Total CoNS 97 32 7 21.9 9 28.1 20 62.5 11 34.4 7 21.9 32 100 9 28.1
CoP S. aureusb 121 81 66 81.5 69 85.2 64 79 47 58 20 24.7 79 97.5 10 12.3
CoN S. aureusa, coagulase-negative S. aureus
CoP S. aureusb, coagulase-positive S. aureus
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